India to United States: Moxifloxacin Export Trade Route
India has recorded 153 verified shipments of Moxifloxacin exported to United States, representing a combined trade value of $4.7M USD. This corridor is served by 20 active Indian exporters, with an average shipment value of $30.7K USD. The leading Indian exporter is EUGIA PHARMA SPECIALITIES LIMITED, which accounts for 34% of total export value with 28 shipments worth $1.6M USD. On the buying side, MYLAN INSTITUTIONAL INC 2898 is the largest importer in United States with $742.1K USD in purchases. The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, MYLAN LABORATORIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED — together control 65% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Moxifloxacin corridor is one of India's established pharmaceutical export routes, with 153 shipments documented worth a combined $4.7M USD. The route is dominated by EUGIA PHARMA SPECIALITIES LIMITED, which alone accounts for roughly 34% of all export value, reflecting the consolidated nature of India's moxifloxacin manufacturing sector.
Across 20 active suppliers, the average shipment value stands at $30.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 75% of all shipments, consistent with moxifloxacin's non-urgent bulk-order profile.
Shipment activity peaks during October–December, with an average transit time of 24 days port-to-port. The route has recorded an annual growth rate of 28.6%, placing it at rank #11 among India's top moxifloxacin export destinations globally.
On the import side, key buyers of Indian moxifloxacin in United States include MYLAN INSTITUTIONAL INC 2898, NORTHSTAR DISTRIBUTION CENTER 8912, AUROBINDO PHARMA USA., INC, and 35 others. MYLAN INSTITUTIONAL INC 2898 is the single largest importer with 16 shipments valued at $742.1K USD.
Route Characteristics
- Average transit24 days
- Peak seasonQ4
- Primary modeSea freight
- Top portSAHAR AIR
Market Position
- Global rank#11
- Annual growth+28.6%
- Demand growth+24.0%
- Regulatory ease77/100
Top 10 Indian Moxifloxacin Exporters to United States
Showing top 10 of 20 Indian suppliers exporting Moxifloxacin to United States, ranked by total trade value (USD)
| Rank | Supplier (Indian Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | EUGIA PHARMA SPECIALITIES LIMITED Avg $56.9K per shipment | 28 | $1.6M | 33.9% |
| 2 | MYLAN LABORATORIES LIMITED Avg $46.2K per shipment | 18 | $831.4K | 17.7% |
| 3 | ALEMBIC PHARMACEUTICALS LIMITED Avg $25.9K per shipment | 24 | $622.0K | 13.3% |
| 4 | MANKIND PHARMA LIMITED Avg $41.9K per shipment | 10 | $419.3K | 8.9% |
| 5 | AUROBINDO PHARMA LIMITED Avg $88.4K per shipment | 4 | $353.8K | 7.5% |
| 6 | MSN LABORATORIES PRIVATE LIMITED Avg $29.2K per shipment | 10 | $291.7K | 6.2% |
| 7 | GLAND PHARMA LIMITED Avg $55.4K per shipment | 4 | $221.7K | 4.7% |
| 8 | LUPIN LIMITED Avg $21.7K per shipment | 8 | $173.4K | 3.7% |
| 9 | GLAND PHARMA LTD Avg $50.2K per shipment | 3 | $150.6K | 3.2% |
| 10 | SOMERSET THERAPEUTICS PRIVATE LIMITED Avg $13.8K per shipment | 1 | $13.8K | 0.3% |
This table shows the top 10 of 20 Indian companies exporting moxifloxacin to United States, ranked by total trade value. The listed exporters are: EUGIA PHARMA SPECIALITIES LIMITED, MYLAN LABORATORIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, MANKIND PHARMA LIMITED, AUROBINDO PHARMA LIMITED, MSN LABORATORIES PRIVATE LIMITED, GLAND PHARMA LIMITED, LUPIN LIMITED, GLAND PHARMA LTD, SOMERSET THERAPEUTICS PRIVATE LIMITED. EUGIA PHARMA SPECIALITIES LIMITED is the dominant supplier with 28 shipments worth $1.6M USD, giving it a 34% market share. The top 3 suppliers together account for 65% of the total trade value on this route.
Showing top 10 of 20 total Indian exporters on the India to United States Moxifloxacin export route.
Top 10 Moxifloxacin Importers in United States
Showing top 10 of 38 known buyers in United States receiving Moxifloxacin shipments from India, ranked by import value
On the receiving end of this trade route, the leading importers of Indian moxifloxacin in United States include MYLAN INSTITUTIONAL INC 2898, NORTHSTAR DISTRIBUTION CENTER 8912, AUROBINDO PHARMA USA., INC,, J. KNIPPER & COMPANY, EVERSANA LIFE SCIENCE SERVICES, among 38 total buyers. The largest importer is MYLAN INSTITUTIONAL INC 2898, accounting for $742.1K USD across 16 shipments — representing 16% of all moxifloxacin imports from India on this route.
| Rank | Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | MYLAN INSTITUTIONAL INC 2898 | 16 | $742.1K | 15.8% |
| 2 | NORTHSTAR DISTRIBUTION CENTER 8912 | 5 | $511.0K | 10.9% |
| 3 | AUROBINDO PHARMA USA., INC, | 9 | $442.3K | 9.4% |
| 4 | J. KNIPPER & COMPANY | 12 | $381.1K | 8.1% |
| 5 | EVERSANA LIFE SCIENCE SERVICES | 7 | $372.3K | 7.9% |
| 6 | XXROBXXDO XXARMXXUSAXXNC | 3 | $331.7K | 7.1% |
| 7 | LIFESTAR PHARMA LLC | 8 | $314.5K | 6.7% |
| 8 | NOVADOZ PHARMACEUTICALS LLC | 8 | $249.6K | 5.3% |
| 9 | J KNIPPER COMPANY | 6 | $157.8K | 3.4% |
| 10 | Lupin Pharmaceutical Inc | 6 | $134.7K | 2.9% |
Showing top 10 of 38 Moxifloxacin importers in United States on this route.
Top 10 Moxifloxacin Formulations Imported by United States
Showing top 10 of 76 product formulations shipped on the India to United States Moxifloxacin route, ranked by trade value
United States imports a wide range of moxifloxacin formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/V — accounts for $480.9K USD across 5 shipments. There are 76 distinct product descriptions in the dataset, reflecting the variety of dosage forms and strengths imported.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/V | 5 | $480.9K | 10.2% |
| 2 | MOXIFLOXACIN HYDROCHLORIDE TABLETS 400MG | 4 | $353.8K | 7.5% |
| 3 | MOXIFLOXACIN HCL INJ 1.6MG/ML 12S US SU6 | 7 | $335.7K | 7.2% |
| 4 | MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% W/V (MOXIFLOXACIN OPHTHALMICSOLUTION USP 0.5% W/V) | 3 | $184.8K | 3.9% |
| 5 | MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5 | 4 | $177.2K | 3.8% |
| 6 | MOXIFLOXACIN OPTH SOLN0.53ML US | 8 | $173.4K | 3.7% |
| 7 | MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0 5 5MG ML | 1 | $172.7K | 3.7% |
| 8 | MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0.5% (5MG/ML) | 3 | $150.6K | 3.2% |
| 9 | MOXIFLOXACIN OS USP 0.5% 3ML 1 S AP US | 2 | $142.6K | 3.0% |
| 10 | MOXIFLOXACIN OPHTHALMIC SOLUTION USP 0 5 W V | 1 | $137.5K | 2.9% |
Showing top 10 of 76 Moxifloxacin formulations imported by United States on this route.
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Sea freight dominates at 75%, typical for bulk pharmaceutical shipments.
Top Ports of Origin
SAHAR AIR handles the highest volume with 14 shipments. Transit time averages 24 days by sea.
Market Dynamics
India's moxifloxacin exports to United States are driven primarily by a handful of large-scale manufacturers. EUGIA PHARMA SPECIALITIES LIMITED with 28 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 20 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, MYLAN LABORATORIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED — together account for 65% of total trade value on this route. The average shipment value of $30.7K USD reflects a mix of bulk commercial orders and smaller specialty shipments.
Beyond the primary product category, shipments on this route include closely related formulations such as moxifloxacin hydrochloride tablets 400mg and moxifloxacin hcl inj 1.6mg/ml 12s us su6, suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.
On the buying side, MYLAN INSTITUTIONAL INC 2898 is the largest importer with 16 shipments worth $742.1K USD — representing 16% of all moxifloxacin imports from India on this route. A total of 38 buyers are active on this corridor.
Route Statistics
- Trade Volume
- $4.7M
- Avg. Shipment
- $30.7K
- Suppliers
- 20
- Buyers
- 38
- Transit (Sea)
- ~24 days
- Annual Growth
- +28.6%
Related Analysis
Reverse Direction
United States → India — Moxifloxacin (Import)Other Moxifloxacin Routes
Unlock the Full India to United States Moxifloxacin Dataset
TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 153 shipments on this route.
Frequently Asked Questions — India to United States Moxifloxacin Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Indian companies export Moxifloxacin to United States?
The leading Indian exporters of Moxifloxacin to United States are EUGIA PHARMA SPECIALITIES LIMITED, MYLAN LABORATORIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED. EUGIA PHARMA SPECIALITIES LIMITED holds the largest market share at approximately 34% of total trade value on this route.
Q What is the total value of Moxifloxacin exports from India to United States?
India exports Moxifloxacin to United States worth approximately $4.7M USD across 153 recorded shipments. The average value per shipment is $30.7K USD.
Q Which ports does India use to ship Moxifloxacin to United States?
The most active port of origin is SAHAR AIR with 14 shipments. Indian exporters primarily use sea freight for this route, with 75% of shipments going by sea and 22% by air.
Q How long does shipping take from India to United States for Moxifloxacin?
The average transit time for Moxifloxacin shipments from India to United States is approximately 24 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during October–December.
Q Is the India to United States Moxifloxacin trade route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 28.6% with demand growth tracking at 24.0%. The route is ranked #11 among India's top Moxifloxacin export destinations globally.
Q How many suppliers are active on the India to United States Moxifloxacin route?
There are currently 20 active Indian suppliers exporting Moxifloxacin to United States. The market is moderately concentrated with EUGIA PHARMA SPECIALITIES LIMITED accounting for 34% of total shipment value.
Q Who are the main importers of Moxifloxacin from India in United States?
The leading importers of Indian Moxifloxacin in United States include MYLAN INSTITUTIONAL INC 2898, NORTHSTAR DISTRIBUTION CENTER 8912, AUROBINDO PHARMA USA., INC,, J. KNIPPER & COMPANY, EVERSANA LIFE SCIENCE SERVICES. MYLAN INSTITUTIONAL INC 2898 is the largest buyer with 16 shipments worth $742.1K USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to United States export trade corridor identified from Indian Customs (DGFT) records for Moxifloxacin.
- 2.Supplier/Buyer Matching: 20 Indian exporters and 38 importers in United States matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 153 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
153 Verified Shipments
20 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists